Suppr超能文献

澳大利亚人群中伴有血小板减少的 RD 的诊断和治疗。

Diagnosis and treatment of RD in an Australasian cohort with thrombocytopenia.

机构信息

Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, Australia.

Northern Blood Research Centre, Kolling Institute of Medical Research, The University of Sydney, Sydney, Australia.

出版信息

Platelets. 2018 Dec;29(8):793-800. doi: 10.1080/09537104.2017.1356920. Epub 2017 Nov 1.

Abstract

-related disorders (-RDs) caused by mutation of the gene which encodes non-muscle myosin heavy-chain-IIA (NMMHC-IIA), an important motor protein in hemopoietic cells, are the most commonly encountered cause of inherited macrothrombocytopenia. Despite distinguishing features including an autosomal dominant mode of inheritance, giant platelets on the peripheral blood film accompanied by leucocytes with cytoplasmic inclusion bodies (döhle-like bodies), these disorders remain generally under-recognized and often misdiagnosed as immune thrombocytopenia (ITP). This may result in inappropriate treatment with corticosteroids, immunosupressants and in some cases, splenectomy. We explored the efficacy of next generation sequencing (NGS) with a candidate gene panel to establish the aetiology of thrombocytopenia for individuals who had been referred to our center from hematologists in the Australasian region in whom the cause of thrombocytopenia was suspected to be secondary to an inherited condition but which remained uncharacterized despite phenotypic investigations. Pathogenic variants were detected in 15 (15/121, 12.4%) individuals and the pathogenecity of a novel variant of uncertain significance was confirmed in a further two related individuals following immunofluorescence (IF) staining performed in our laboratory. Concerningly, only one (1/17) individual diagnosed with -RD had been referred with this as a presumptive diagnosis, in all other cases (16/17, 94.1%), a diagnosis was not suspected by referring clinicians, indicating a lack of awareness or a failing of our diagnostic approach to these conditions. We examined the mean platelet diameter (MPD) measurements as a means to better identify and quantify platelet size. MPDs in cases with -RDs were significantly larger than controls ( < 0.001) and in 91% were greater than a previously suggested threshold for platelets in cases of ITP. In addition, we undertook IF staining in a proportion of cases and confirm that this test and/or NGS are satisfactory diagnostic tests. We propose that fewer cases of -RDs would be missed if diagnostic algorithms prioritized IF and/or NGS in cases of thrombocytopenia associated with giant platelets, even if döhle-like bodies are not appreciated on the peripheral blood film. Finally, our report describes the long-term use of a thrombopoietin agonist in a case of -RD that had previously been diagnosed as ITP, and demonstrates that treatment with these agents may be possible, and is well tolerated, in this group of patients.

摘要

与 基因变异相关的疾病(-RDs)会导致非肌肉肌球蛋白重链-IIA(NMMHC-IIA)编码异常,该基因是造血细胞中重要的运动蛋白,是遗传性巨血小板减少症最常见的病因。尽管这些疾病具有常染色体显性遗传模式、外周血片中出现巨大血小板,且伴有白细胞胞质内包涵体(Döhle 小体)等特征,但由于这些疾病通常未被充分认识,且经常被误诊为免疫性血小板减少症(ITP),因此诊断仍存在困难。这可能导致皮质类固醇、免疫抑制剂的不当使用,在某些情况下还会导致脾切除术。我们通过候选基因panel 对下一代测序(NGS)进行了探索,对来自澳大利亚地区血液科医生推荐的个体的血小板减少症病因进行了研究,这些患者的血小板减少症病因疑似为遗传性疾病,但经过表型研究后仍未明确病因。在 121 名个体中,有 15 名(15/121,12.4%)个体检测到致病性变异,在进一步的 2 名相关个体中,通过我们实验室进行的免疫荧光(IF)染色,证实了一种新的意义未明的致病性变异。令人担忧的是,仅有 1 名(1/17)被诊断为 -RD 的患者是以该疾病为假定诊断进行转诊,在所有其他情况下(16/17,94.1%),转诊医生未怀疑该疾病,这表明对这些疾病缺乏认识或我们的诊断方法存在缺陷。我们检测了平均血小板直径(MPD)作为一种更好地识别和量化血小板大小的方法。-RDs 患者的 MPD 显著大于对照组(<0.001),91%的患者 MPD 大于之前建议的 ITP 病例中血小板的阈值。此外,我们对部分病例进行了 IF 染色,证实该检测方法和/或 NGS 是满意的诊断检测方法。我们提出,如果在伴有巨大血小板的血小板减少症病例中,诊断算法优先考虑 IF 和/或 NGS,那么 -RDs 病例的漏诊率将会降低,即使外周血片中未观察到 Döhle 小体。最后,我们的报告描述了一例 -RD 患者长期使用血小板生成素激动剂的情况,该患者此前被诊断为 ITP,这表明在这组患者中,这些药物的治疗是可行的,且耐受良好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验